Hcw Biologics Inc. · NASDAQ:HCWB
Hcw Biologics — Investor Presentation (March 2026)
20 slides from Hcw Biologics's investor presentation, March 2026
Slide 1: Transformative Fusion Immunotherapeutics
Transformative Fusion Immunotherapeutics Revolutionary Treatments for Autoimmune Disease, Cancers, and Senescence-Associated Dysplasia NASDAQ: HCWB MARCH 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain information about HCW Biologics Inc. (the “Company”) contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation
Slide 3: About HCW Biologics Inc.
About HCW Biologics Inc. A US-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support and treat diseases promoted by chronic inflammation. We Our Company also have certain fusion compounds that are commercial-ready for use as reagents in the prod
Slide 4: Our Founder & CEO: Proven Track Record for Success
Our Founder & CEO: Proven Track Record for Success Founded multiple successful start-ups, which delivered superior returns to investors. • Founded HCW Biologics Inc. in April 2018. Provided all the capital for seed and start-up financing. Participated in several other rounds of financing. Total inve
Slide 5: Two Proprietary Drug Discovery & Development Platform Technologies
TWO Proprietary Drug Discovery & Development Platform Technologies for the Creation of Novel Immunotherapeutic Fusions TOBITM Platform Technology TRBC Platform Technology “Tissue FactOr-Based FusIon” “T-Cell Receptor β-Chain Constant Region” HCW BIOLOGICS 5
Slide 6: Straightforward Manufacturing Process of HCW's Fusion Immunotherapeutic Compounds
Straightforward Manufacturing Process of HCW’s Fusion Immunotherapeutic Compounds HCW fusion compounds HCW fusion immunotherapeutic compounds HCW BIOLOGICS 6
Slide 7: A Novel Immunotherapeutic Approach
A Novel Immunotherapeutic Approach Autoimmune Diseases Cancer & Other Senescence-Associated Dysplasia HCW9302 Treg Cells HCW11-006 (Multi-Functional HCW11-040 (2nd-Gen Immune HCW11-018b (“BIG BITE”, 2nd-Gen Immune Cell Stimulator) Checkpoint Inhibitor) T-Cell Engager) Expansion & Functionality Immun
Slide 8: Lead Product Candidates
Lead Product Candidates HCW9206 – Generates highly functional CAR-T cells and lowers cost of production. Commercial-Ready Programs HCW9201 – Generates highly functional Memory-Like NK cells and lowers cost of production. HCW9302 – Designed to expand Treg cells and increase their Clinical-Stage Progr
Slide 9: Commercial-Ready HCW9206 as Reagent for CAR-T Manufacturing
Commercial-Ready HCW9206 as Reagent for CAR-T Manufacturing (Ex Vivo) • Designed to increase persistence and functionality of CAR-Ts, enhancing their efficacy for treatment of infectious disease and cancer. Also expected to lower treatment costs by streamlining production.* • HCW9206 is ready for co
Slide 10: Clinical-Stage HCW9302: Best-in-Class IL-2-Based Immunotherapeutic
Clinical-Stage HCW9302: Best-in-Class IL-2-Based Immunotherapeutic for Regulatory-T-Cell Expansion for Autoimmune Diseases Clinical Development Strategy HCW9302 HCW9302 rhIL-2 • HCW9302 is well tolerated and can be administered subcutaneously at a dosing range that expands and activates Treg cells b
Slide 11: HCWALO101: Phase 1 Study of HCW9302 for Alopecia Areata
HCWALO101: Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata Phase 1 Dose Escalation to evaluate the safety profile and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of HCW9302 in subjects with alopecia areata (AA) (ClinicalTrials.gov ID: NCT07049
Slide 12: HCW11-006: Activation and Expansion of Immune Cells
IND-ENABLING STAGE IMMUNE CELL STIMULATOR HCW11-006: Activation and Expansion of Immune Cells • A multi-cytokine fusion for immune cell activation and expansion. • HCWB has licensed HCW11-006 to Trimmune Biotech for IL-7 in vivo applications. • Upfront license fee with value of $7.0 million in cash
Slide 13: HCW11-018b: Lead Tetravalent BIG-BiTE Program
IND-ENABLING STAGE T-CELL ENGAGER HCW11-018b: HCWB’s Lead Tetravalent “BIG-BiTE” Program • HCW11-018b was selected as lead compound from those created for the second-generation. The Big BiTE T-Cell Engager Program was created with the TRBC Platform. TGF-βRII • Designed to address key challenges for
Slide 14: HCW11-040: Second-Generation Immune Checkpoint Inhibitor
IND-ENABLING STAGE IMMUNE CHECKPOINT INHIBITOR HCW11-040: Second-Generation Immune Checkpoint Inhibitor (“ICI”) • HCW11-040 is the lead candidate of the family of compounds TGF-βRII created as a second-generation immune checkpoint inhibitor using the TRBC platform. • Unique combination of cytokines
Slide 15: Product Pipeline
Product Pipeline NOTE: a. HCW9206 & HCW9201 are commercial-ready proprietary molecules for use as reagents in the production of immunotherapeutics to treat infectious diseases and cancer. b. Beijing Trimmune Biotech Co., Ltd. holds the exclusive worldwide license rights to HCW11-006 for in vivo appl
Slide 16: Projected Clinical Milestones
Projected Clinical Milestones Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2026 2026 2026 2026 2027 2027 2027 2027 2028 2028 Preliminary human data readout from HCW9302 clinical study, indicators for effective expansion of Treg cells HCW9302 full human data readout from Phase 1 clinical study HCW9302 Phase 2 clini
Slide 17: Financial Strategy
Financial Strategy The Company is focused on attracting fundamental investors who would Private Placements be strategic investors focused on the long-term scientific and medical potential of biotechnology, especial our novel immunotherapeutics. Direct Registered and The Company has utilized S-1 and
Slide 18: Senior Management Team
Senior Management Team Chief Science Officer, VP Clinical Operations • Joined HCWB in 2019 and previously served as Senior Vice President of Research and Development at Altor. • Highly involved in discovery, research, manufacturing, and clinical development of ALT-803, known as ANKTIVA®. • Ph.D. deg
Slide 19: Senior Management Team (continued)
Chief Financial Officer • Joined HCWB in 2019, with mandate to complete pre-IPO private financing and IPO. • Prior to HCWB, Director in Transaction Services at PwC and served as CFO at two other startups. • Private equity investing at Apax Partners, with biotech focus. • MBA degree from NYU, BA degr
Slide 20: Thank You!
Thank You! Rebecca Byam CFO HCW Biologics Inc. (NASDAQ: HCWB) 2929 North Commerce Parkway Miramar, FL 33025 Email: [email protected] Website: https://hcwbiologics.com/ HCW BIOLOGICS 20